ZJY-54

CAT: 0804-HY-168968SSize: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-168968SSize:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ZJY-54 is an orally active dual-target inhibitor of EGFR/LSD1, with IC50 values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity[1].
UNSPSC
12352211
Target
EGFR; Histone Demethylase
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
COC1=C(C=C(C(N2C[C@@H](CC2)N(C)C)=C1)NC(C=C)=O)NC3=NC(C4=CN(C([2H])([2H])[2H])C5=CC=CC=C54)=CC=N3
Molecular Formula
C29H30D3N7O2
Molecular Weight
514.64
References & Citations
[1]Zhang J, et al. Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers. J Med Chem. 2025 Mar 13;68 (5) :5954-5972.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products